LTR Pharma is pleased to announce the appointment of Dr Andrew Y. Sun, M.D., a fellowship-trained urologist and nationally recognised expert in male sexual and reproductive medicine, to its Scientific Advisory Board.
Based in Texas, Dr Sun brings extensive experience in prescribing PDE5 treatment protocols and will advise on integrating LTR’s intranasal therapies ROXUS ® and SPONTAN ® – into treatment pathways for erectile dysfunction (ED), particularly for patients experiencing side effects with existing oral medications.
Dr Sun is Director of Men’s Health at Urology Partners of North Texas, one of the state’s largest men’s health clinics. A Harvard-trained urologist with residency at the Cleveland Clinic and fellowship at UCLA, he specialises in erectile dysfunction, infertility, hormone management, and Peyronie’s disease.
Dr Andrew Sun, said:
“A sizeable portion of patients experience problematic side effects from higher-dose PDE5 tablets – back pain, heartburn, joint aches – that affect quality of life and intimacy. ROXUS AND SPONTAN offer the rapid onset men want without the systemic side effects that often compromise their experience.”